<article>Continuing its investment spree, Japan&#8217;s<a href="https://www.dealstreetasia.com/?s=SoftBank"> SoftBank</a>, through its<a href="https://www.dealstreetasia.com/?s=Vision%20Fund" target="_blank" rel="noopener"> Vision Fund</a>, has led a $1.1 billion equity investment in Swiss healthcare firm <a href="https://www.dealstreetasia.com/?s=Roivant%20Science" target="_blank" rel="noopener">Roivant Sciences</a>, the company announced on Thursday.</article>

Continuing its investment spree, Japan&#8217;s<a href="https://www.dealstreetasia.com/?s=SoftBank"> SoftBank</a>, through its<a href="https://www.dealstreetasia.com/?s=Vision%20Fund" target="_blank" rel="noopener"> Vision Fund</a>, has led a $1.1 billion equity investment in Swiss healthcare firm <a href="https://www.dealstreetasia.com/?s=Roivant%20Science" target="_blank" rel="noopener">Roivant Sciences</a>, the company announced on Thursday.
The investment, which also saw participation from existing shareholders, is intended to accelerate the launch of new subsidiaries within and beyond the biopharmaceutical industry, Roivant said in a press statement.
“We are pleased to welcome the SoftBank Vision Fund as a new investor in Roivant, and we are grateful for the continued support of our existing shareholders,” said Vivek Ramaswamy, Founder and CEO of Roivant.
“I admire SoftBank’s long-term vision and I believe they will add significant strategic value to Roivant in the next phase of our growth.”
Located at Basel, Roivant focuses on developing and commercializing novel therapies through subsidiaries, all of which involve word &#8216;vant’. These include Axovant (neurology), Myovant (women’s health and endocrine diseases), Dermavant (dermatology), Enzyvant (rare diseases), and Urovant (urology).
Datavant, a new technology-focused subsidiary, will be the first company in the Roivant family to operate outside of traditional biopharmaceutical development. It aims to dissolve barriers between siloed healthcare datasets in order to unlock novel insights and reduce the time and cost of delivering innovative medicines to patients.
“Roivant has attracted world-class talent in its pursuit of developing and commercializing drugs that target large unmet medical needs,” said Akshay Naheta, Managing Director of SoftBank Group International.
“We are impressed with the ambition and track record of the Roivant team and look forward to supporting them in the next step of their journey, as they look to effectively harness technology and leverage big data across all aspects of their business.”
Also Read:
<a href="https://www.dealstreetasia.com/stories/72499-72499/" target="_blank" rel="noopener">SoftBank leads $360m funding in cancer screening firm Guardant Health</a>
<a href="https://www.dealstreetasia.com/stories/sunsoftbank-reverse-fortunes-india-74184/" target="_blank" rel="noopener">SoftBank looks to reverse fortunes in India</a>

The investment, which also saw participation from existing shareholders, is intended to accelerate the launch of new subsidiaries within and beyond the biopharmaceutical industry, Roivant said in a press statement.

Japan's SoftBank leads $1.1b investment in Swiss firm Roivant Sciences

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Japan's SoftBank leads $1.1b investment in Swiss firm Roivant Sciences

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief